Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies

• Roger H. Kobayashi,
• Sudhir Gupta,
• Isaac Melamed,
• J. Fernando Mandujano,
• Ai Lan Kobayashi,
• Bruce Ritchie,
• Bob Geng,
• Thomas Prescott Atkinson,
• Syed Rehman,
• Eva Turpel-Kantor,
• Jiří Litzman

Affiliations

Roger H. Kobayashi

UCLA School of Medicine, Los Angeles, CA, United States

Sudhir Gupta

Division of Basic and Clinical Immunology, University of California, Irvine, Irvine, CA, United States

Isaac Melamed

IMMUNOe Research Center, Centennial, CO, United States

J. Fernando Mandujano

Pediatric Pulmonary Associates of North Texas, Frisco, TX, United States

Ai Lan Kobayashi

Midlands Pediatrics, Papillion, NE, United States

Bruce Ritchie

Divisionof Hematology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada

Bob Geng

Divisions of Adult and Pediatric Allergy and Immunology, University of California, San Diego, La Jolla, CA, United States

Thomas Prescott Atkinson

Department of Pediatric Allergy, Asthma and Immunology, University of Alabama, Birmingham, AL, United States

Syed Rehman

Allergy and Asthma Center Inc., Toledo, OH, United States

Eva Turpel-Kantor

0Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria

Jiří Litzman

1Department of Clinical Immunology and Allergology, St Anne’s University Hospital in Brno, Faculty of Medicine, Masaryk University, Brno, Czechia